Business Context and Reporting Period
Immuneering Corporation filed a Form 8-K dated June 14, 2023, reporting the results of its Annual Meeting of Stockholders held on that date. The company’s Class A common stock trades on Nasdaq under the symbol IMRX.
Meeting Participation and Voting Results
- 22,610,810 shares were present in person or represented by proxy, equal to approximately 77.3% of outstanding Class A common stock as of the April 20, 2023 record date.
- Peter Feinberg was elected as a Class II director to serve until the 2026 Annual Meeting.
- Laurie B. Keating was elected as a Class II director to serve until the 2026 Annual Meeting.
- Stockholders ratified the appointment of RSM US LLP as the independent registered public accounting firm for the year ending December 31, 2023.
Vote Details
| Proposal | For | Against | Withheld/Abstained | Broker Non-Votes |
|---|---|---|---|---|
| Election of Peter Feinberg | 18,604,285 | 0 | 659,292 withheld | 3,347,233 |
| Election of Laurie B. Keating | 18,640,672 | 0 | 622,905 withheld | 3,347,233 |
| Ratification of RSM US LLP | 22,595,867 | 14,843 | 100 abstained | 0 |
Financial Metrics and Material Changes
This filing is limited to annual meeting voting results. It does not provide revenue, profit, cash flow, margins, debt, liquidity, financial guidance, or other operating metrics, and it does not report material changes versus a prior comparable period.
Outlook, Risks, and Unusual Items
No management outlook, risk updates, contingencies, or unusual financial items are disclosed in the filing. The principal governance items were the election of two directors and approval of the company’s independent auditor.
Key Facts to Verify
- Confirm the continued service terms of Peter Feinberg and Laurie B. Keating through the 2026 Annual Meeting.
- Confirm that RSM US LLP remains the company’s independent registered public accounting firm for the year ending December 31, 2023.
- Review the company’s subsequent periodic filings for financial results, liquidity, cash runway, operating developments, and updated risks, none of which are provided here.